Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.
about
Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program.Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis.Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines.Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.Chemo-selection with docetaxel, cisplatin and 5-fluorouracil (TPF) regimen followed by radiation therapy or surgery for pharyngeal and laryngeal carcinoma.A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA).Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis.
P2860
Q30847864-384B6CE6-0DBF-4B1A-A68E-B4157EA54AA1Q33584160-4C5A26C9-0E0C-4B4F-81FF-F4F213A18B1BQ34511068-195112C9-02BF-4C13-8312-CD1C478523DDQ35674153-98F59C1D-90C4-414B-8AD5-C021E494ECA7Q38414294-4C494FB7-1519-4B7D-9C4E-E3166677F06AQ39317847-62809B3C-BB2D-41C6-A235-F668A1706385Q40100374-450F9B5E-47F5-4DCF-9FCA-590D1048B5ABQ47375559-B132F4D5-DA50-4CAB-9AD5-E2A995F7F67DQ47926809-F488DC2C-38C9-4516-A123-F486093D4A56Q49650663-C44C70E5-4DEE-4EFB-8E43-D8E8DE8A25DEQ51425302-C6D35A72-09C7-49CC-94BE-B2EE296800FEQ53673558-D6806D90-9A25-4694-B2E3-B1E61039D077Q54963459-7D3C99DC-E9DC-4318-8412-FBE4F6E9842F
P2860
Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Pharmacoethnicity of docetaxel ...... ished phase II and III trials.
@en
Pharmacoethnicity of docetaxel ...... ished phase II and III trials.
@nl
type
label
Pharmacoethnicity of docetaxel ...... ished phase II and III trials.
@en
Pharmacoethnicity of docetaxel ...... ished phase II and III trials.
@nl
prefLabel
Pharmacoethnicity of docetaxel ...... ished phase II and III trials.
@en
Pharmacoethnicity of docetaxel ...... ished phase II and III trials.
@nl
P2093
P2860
P1476
Pharmacoethnicity of docetaxel ...... lished phase II and III trials
@en
P2093
Hiroaki Ohnaka
Hitoshi Tsukamoto
Kyohei Watanabe
Mikio Masada
Nobuyuki Goto
Toshiaki Nakamura
Yuichiro Kayano
P2860
P2888
P304
P356
10.1007/S10147-011-0349-5
P50
P577
2011-11-18T00:00:00Z